Over-ground walking in Parkinson’s disease: A pilot study utilizing a portable metabolic analyzer

Alyssa D. Stookey¹, Frederick M. Ivey¹,², Jessica E. Hammers¹, Lisa M. Shulman², Karen Anderson³, Leslie I. Katzel⁴,⁵*

¹VA Maryland Exercise and Robotics Center of Excellence, Baltimore, USA
²Department of Neurology, University of Maryland School of Medicine, Baltimore, USA
³Department of Psychiatry, University of Maryland School of Medicine, Baltimore, USA
⁴Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, USA; *Corresponding Author: lkatzel@grecc.umaryland.edu
⁵Baltimore VA Medical Center, Geriatrics Research Education and Clinical Center (GRECC), Baltimore, USA

Received 2 October 2012; revised 5 November 2012; accepted 11 November 2012

ABSTRACT

Alterations in gait biomechanics are common during early stages of Parkinson’s disease (PD), potentially elevating energy requirements of walking and leading to impaired economy of gait. Although gait economy is traditionally assessed during treadmill walking with simultaneous oxygen consumption (VO₂) monitoring, treadmill gait mechanics, particularly in PD, may be different from over-ground walking mechanics, possibly providing a distorted picture of true gait economy. Currently, no studies have directly examined the energy cost of over-ground walking in PD patients. The purpose of this study was to test the feasibility of measuring energy expenditure during over-ground walking in mild to moderate PD using portable gas exchange monitoring technology. Additionally, we sought to determine whether energy expenditure, as assessed through VO₂ measures, related to disease severity for PD. Seventeen PD patients underwent separate 6-minute walk (6MW) tests both with and without the COSMED K4b2 portable oxygen monitoring system. Gait economy was calculated as measured VO₂ during 6MW divided by the predicted VO₂ for non-PD age-matched subjects, according to a standard estimation equation utilizing ground speed. Distance covered during the 6MW with the portable system (420 ± 12 meters) was highly correlated (r = 0.96, p < 0.001) to distance without the system (442 ± 135 meters) indicating that the lightweight equipment did not confound walking ability in these participants. Mean VO₂ during the 6MW (16.0 ± 5.5 mL/kg/min) was 74% of mean VO₂ peak for this sample, and 16 out of 17 subjects had impaired gait economy. The degree of gait economy impairment was not related to scores on either UPDRS total or motor. Our results demonstrate that PD patients use extraordinarily high percentage of VO₂ peak for normal floor walking, and show impaired gait economy relative to prediction equations. Interestingly, the degree of elevated energy expenditure during gait did not relate to disease severity.

Keywords: Gait Economy; Oxygen Consumption; K4b2

1. INTRODUCTION

Gait impairment is one of the cardinal symptoms of Parkinson’s Disease (PD). Alterations in the biomechanics of gait, such as decreased stride length, increased stride length variability and reduced gait speed, are common even in early-stage PD [1-3]. Most often, PD patients attempt to compensate for short steps by increasing gait cadence, thereby potentially elevating energy requirements of usual pace walking. Increased energy expenditure during walking, manifested as higher oxygen consumption (VO₂), reflects inefficient gait or lower economy of gait [4], with activities being performed at a higher percentage of an individual’s maximal or peak aerobic capacity (VO₂ peak). The clinical significance is that impaired economy of gait and decreased physiological reserve often lead to increased fatigue and reduced endurance, thereby limiting functional independence and sustainability of activities of daily living (ADLs).

Measurement of gait economy using VO₂ measurements is traditionally done during submaximal treadmill walking, but this technique is arguably confounded by a
Advancements in portable VO2 measurement technologies to accurately assess gait efficiency in PD. Recent advancements in portable VO2 measurement technologies have opened many possibilities that stationary metabolic equipment never afforded.

The 6-minute walk (6MW) is a test commonly used to assess longer distance ambulatory capacity over-ground. Hence, we chose to combine state-of-the-art portable metabolic monitoring equipment (COSMED USA; Chicago, IL) with 6MW testing for the first time in PD to directly examine the energy costs of over-ground walking (economy of gait) in mild to moderately severe PD patients. The specific aims of this pilot project were to test the feasibility of measuring submaximal energy expenditure (VO2) during the 6MW in mild to moderate PD using the K4b2 portable oxygen monitoring system, and to determine whether submaximal energy expenditure related to commonly applied disease severity scales (UPDRS).

2. METHODS

2.1. Subjects

This study was approved by the Institutional Review Board at the University of Maryland Baltimore and written informed consent was obtained from each participant. Seventeen subjects with mild to moderately severe PD were recruited from the University of Maryland Parkinson’s Disease and Movement Disorders Center, the Baltimore VA Medical Center Parkinson’s Disease Clinic and via media advertisements. Each participant agreed to participate in a larger randomized trial (beyond the scope of this paper) examining the effects of exercise training on executive function in PD. During the initial history and physical examination, the Hoehn and Yahr (HY) scale [6] and Unified Parkinson’s Disease Rating Scale (UPDRS) [7] were administered by a neurologist (LMS) with expertise in movement disorders. Study inclusion criteria were: 1) diagnosis of levodopa-responsive PD characterized by 2 of 3 cardinal signs (resting tremor, bradykinesia, rigidity; 2) HY stage 2 to 3 (while “on” for motor fluctuations); 3) presence of mild to moderate gait impairment, (score of 1 or 2 on the UPDRS questions #29 Gait or #30 Postural Stability); and 4) unlikely to require PD medication adjustment for 4 months. Study exclusion criteria included: 1) folstein mini mental status examination score [8] less than 23; 2) unstable cardiac, pulmonary, liver or renal disease; 3) poorly controlled hypertension or diabetes; 4) anemia, orthopedic or chronic pain condition restricting exercise; 5) severe depression or other unstable psychiatric condition; and 6) >20 minutes of aerobic exercise more than 3 times per week (to avoid prior training effect).

2.2. Assessments

All physical performance measures used in this sub-study were performed on separate days to avoid the confounding effects of fatigue. Further, all study evaluations (rating scales and functional tests) were performed in the early afternoon while the subjects were “on” or within 3 hours of medication intake. By performing the tests at the same time of day we attempted to control for confounding effects of medication timing issues. Subjects used an additional dose of medication to maintain the “on” state for assessment when necessary.

2.3. Exercise Treadmill Test with Measurement of VO2 Peak

After an initial screening graded exercise test performed on a separate day to exclude subjects with previously undiagnosed silent ischemia, cardiac arrhythmias or severe exercise-induced hypotension, subjects underwent a progressively graded exercise treadmill test to voluntary exhaustion with measurement of VO2 peak using a stationary Quark Cardio Pulmonary Exercise Testing metabolic analyzer (COSMED, USA; Chicago, IL) as previously described [9]. Oxygen consumption, carbon dioxide production, and minute ventilation were measured breath-by-breath and values averaged for 20 second intervals. Subjects were instructed not to talk during the test as this affects the depth of breathing and gas exchange. The VO2 peak was based on the mean of the final two 20 second averages obtained during the final stage of the test. The results of this test were compared with submaximal over-ground measurements to ascertain what percentage of peak VO2 was required for usual floor walking.

2.4. 6MW

On separate testing days, the 6MW tests were performed both with and without the COSMED K4b2 portable oxygen monitoring system. Subjects were instructed to cover as much distance as possible during the 6 minutes. Both tests were conducted down the same hospital corridor with subjects turning every 100 feet, as prompted by orange traffic cones. For safety reasons, given concerns that subjects might not tolerate walking with the portable metabolic system, and given their increased fall risk, we decided not to perform the two tests in a random order as the first uninstrumented test allowed us to ob-

Copyright © 2012 SciRes.
serve their “natural” gait and walking patterns and potentially exclude subjects who were unable to complete the walks. There were no adverse events during the walks, and the portable system was well tolerated, with all of the subjects completing both walks. The staff was blinded to the results of the first test.

2.5. Portable Oxygen Monitoring

The K4b2 portable system, weighing less than 1 kg, was worn on the chest, consisting of a small battery pack and portable gas analyzer. Breath-by-breath analysis was obtained using a flexible rubber facemask with flowmeter that attached to the portable system. To enhance comfort and familiarity, participants underwent a period of standing acclimatization, with the portable gear in place, prior to performing the 6MW test. Additionally, before beginning the 6MW test, participants sat quietly for 5 minutes while wearing the portable system. Participants were instructed not to talk during the walk to avoid affecting depth of breathing and gas exchange measurements. Based on K4b2 portable monitoring data obtained during the final 3 minutes of the 6MW tests, we calculated mean VO2.

2.6. Economy of Gait

Economy of gait was calculated as the measured VO2 during the 6MW divided by the predicted VO2 for non-PD aged-matched subjects based on the commonly accepted American College of Sports Medicine equation for walking accounting for both speed and grade [10].

\[
\text{VO}_2 = \text{horizontal component} + \text{vertical component} + \text{resting component} \\
\text{VO}_2 = 0.1\text{(speed)} + 1.8\text{(speed)}(\text{fractional grade}) + 3.5 \\
\]

In the case of the over-ground 6MW test, there was obviously no vertical element or grade to consider, such that variability in the predicted level was entirely a function of floor walking speed. Therefore, with grade at 0% the equation for predicted VO2 at a given floor walking speed was reduced to:

\[
\text{VO}_2 = 0.1\text{(speed)} + 3.5 . \\
\]

According to our method for assessing gait economy in this pilot study, if the PD participant’s VO2 for a given walking speed was higher than the predicted VO2 for that gait speed, they were labeled as having impaired economy of gait.

2.7. UPDRS

UPDRS, a commonly applied index for disease severity, was administered and scored by a neurologist (LMS) with expertise in movement disorders. The Total UPDRS includes three subscales: Mentation, Behavior and Mood (Part I), Activities of Daily Living (Part II), and the Motor Examination (Part III). Both the total score and motor scores were used to compare with over-ground gait economy.

3. STATISTICAL ANALYSIS

SPSS Predictive Analytics Software 18.0 (SPSS, Inc., Chicago, IL) was used for statistical analysis. Descriptive statistics are expressed as mean ± standard deviation (SD). Pearson’s correlation coefficients were used to quantify strength of relationships between variables. An independent samples t-test was performed to compare measured versus predicted VO2 during the 6MW and a paired samples t-test was performed to compare mean 6MW distance with and without the portable system. All statistical tests were two sided, with P value < 0.05 required for significance.

4. RESULTS

A total of 17 subjects, 12 male and 5 female, with a mean age 66.5 ± 9.5 years (range 46 to 79 years) were included in the analyses for this study. The mean HY score, UPDRS total score, and UPDRS motor score were reflective of mild to moderate disability. These and other subject characteristics are summarized in Table 1.

The mean distance covered during the uninstrumented 6MW was 420 ± 120 meters and the distance covered with subjects wearing the portable oxygen system was virtually identical at 442 ± 135 meters, indicating that the monitoring equipment did not in any way alter the capacity

<table>
<thead>
<tr>
<th>Table 1. Subject characteristics and severity of PD.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ± SD</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>UPDRS total score</td>
</tr>
<tr>
<td>UPDRS motor</td>
</tr>
<tr>
<td>HY stage</td>
</tr>
<tr>
<td>HY stage 2.0</td>
</tr>
<tr>
<td>HY stage 2.5</td>
</tr>
<tr>
<td>HY stage 3.0</td>
</tr>
<tr>
<td>6MW VO2 (mL/kg/min)</td>
</tr>
<tr>
<td>Peak VO2 (mL/kg/min)</td>
</tr>
<tr>
<td>Self-selected walking speed (mph)</td>
</tr>
<tr>
<td>6MW distance (m)</td>
</tr>
</tbody>
</table>
to ambulate over-ground. There was no significant difference in distance walked between the two 6MW tests (p = 0.88). Furthermore, the distance covered between the 2 tests was highly correlated (r = 0.96, p < 0.001, Figure 1), and the portable VO$_2$ system was well tolerated, with no falls or adverse events during testing.

Mean VO$_2$ during the 6MW was 16.0 ± 5.5 mL/kg/min, which represented 74% ± 21% of the mean VO$_2$ peak for this sample. In three of the subjects, the VO$_2$ measured during the 6MW exceeded the values obtained during their peak effort treadmill test. There was a significant difference between mean measured submaximal VO$_2$ and mean predicted VO$_2$ (10.5 ± 2.3 mL/kg/min) (p < 0.001), with measured values significantly higher than predicted (p < 0.001; Figure 2). In 16 of 17 subjects, the measured VO$_2$ values during the 6MW exceeded the predicted values for non-PD subjects based on gait velocity (Figure 2), consistent with impaired economy of gait. On average, our subjects utilized 53% more oxygen than expected (Figure 3).

Our chosen gait economy index (measured VO$_2$ during 6MW divided by predicted VO$_2$ according to gait speed) was not related to either UPDRS total (r = -0.093) or motor (r = 0.087) scale scores. Mean submaximal VO$_2$ was also not related to UPDRS total (r = -0.13) or motor (r = -0.33). However, mean VO$_2$ during the 6MW correlated with walking speed (r = 0.67). The distance covered during the 6MW negatively correlated with UPDRS motor (r = -0.5), but not UPDRS total.

Figure 1. Distance covered without and with portable system.

Figure 2. Measured submaximal VO$_2$ versus predicted.

5. DISCUSSION

This study was the first to use novel, state-of-the art portable technology to directly examine the energy cost of over-ground walking in mild to moderate PD. Importantly, our study demonstrated the feasibility of using portable oxygen monitoring during over-ground walking in this population. According to our data, the K4b2 portable device was lightweight enough so as not to interfere with walking performances as evidenced by the identical 6MW distances between test one and test two. Therefore, this portable technology appears to be a suitable tool for use in this population. Our results are also the first to demonstrate the extent of over-ground gait economy impairment in PD and that over-ground energy expenditure is not predicted by commonly applied disease severity scales.

Few studies have directly measured walking economy based on submaximal oxygen consumption measures in PD. Of these, all assessed economy of gait during treadmill walking [9,11], which, as mentioned previously, is confounded by several features. Christiansen, et al. [11] examined gait economy at various treadmill walking speeds in subjects with PD compared to healthy subjects without PD. They reported that submaximal VO$_2$ was 6 to 10% higher in people with PD at various walking speeds above 1 mph. This stands in contrast to our current results, which suggest a much higher VO$_2$ than predicted for a given rate of speed. In fact, our participants were consuming 53% more oxygen than expected during the over-ground 6-minute walk test. Similarly, Katzel et al. [9] measured submaximal VO$_2$ during treadmill walking at self-selected speed and showed a much greater impairment in walking economy. In that submaximal treadmill study, PD participants were operating at 64% of their measured VO$_2$ peak, whereas the over-ground walking in this study required a mean 74% of VO$_2$ peak. This
that higher than normal submaximal VO₂ levels translate
previously reported in non-PD studies, supporting the idea
this study for PD were quite a bit lower than those pre-
extended period of time. The 6MW distances observed in
ability of this population to sustain normal ADLs for any
over-ground walking in PD, perhaps explaining the in-
economy.

Our cohort of 17 PD subjects had an average VO₂
peak of 22.9 ± 9.3 mL/kg/min, which is consistent with
values reported in the literature for this population [9,13].
Previous reports indicate that mild to moderate PD pa-
tients have VO₂ peak values that are 20% - 25% lower
than healthy age-matched controls [13,14]. An even more
discouraging picture emerges when this impairment in
VO₂ peak is coupled with lower gait economy during
over-ground walking in PD, perhaps explaining the in-
ability of this population to sustain normal ADLs for any
extended period of time. The 6MW distances observed in
this study for PD were quite a bit lower than those pre-
viously reported in non-PD studies, supporting the idea
that higher than normal submaximal VO₂ levels translate
into clinically relevant functional limitations. Our PD
subjects’ 6MW distances were comparable to the values
reported in the existing literature for mild to moderate
PD [9,15] and were 18% lower than that predicted for
healthy, non-PD individuals according to an established
prediction equation, which takes into account age, gender,
and weight [16]. This is consistent with Katzel, et al. [9]
who reported a 17% difference.

Researchers have hypothesized that tremor, prominent
at rest in people with PD, may play a role in economy of
gait for individuals in early stages of PD due to the poten-
tial effect on resting energy expenditure. However,
Christiansen, et al. [11] reported no significant difference
in resting energy expenditure between PD patients (3.5 ±
0.7 mL/kg/min) and healthy individuals (3.5 ± 0.5
mL/kg/min) (p = 0.97). Thus, it is reasonable to conclud
that elevations in energy expenditure during submaximal
walking are not a function of elevated resting VO₂. Our
data appears similarly unaffected by resting VO₂ given
an average resting level of 3.80 ± 0.98 mL/kg/min in the
17 subjects studied.

Our results showed that economy of gait during
over-ground walking was not related to PD severity. This
is also consistent with previous research demonstrating
no relationship between UPDRS total or motor and
energy of gait during treadmill walking [11,13]. Chris-
tiansen, et al. [11], reported no relationship between
submaximal VO₂ and UPDRS total during submaximal
treadmill walking, which combined with our over-ground
findings call into question the utility of the UPDRS for
predicting this particular aspect of post PD function. A
lack of relationship between UPDRS and these measures
may partly be a consequence of under-emphasis on am-
bulatory function and associated elements of endurance
by this severity scale.

Our pilot results should be interpreted with caution
based upon a number of clear limitations. First, our study
determined economy of gait based upon a commonly
accepted predicted VO₂ equation instead of actually
measuring VO₂ in age and gender matched non-PD,
healthy controls. However, it would have been difficult
to find healthy subjects who walk slowly enough to
match our PD subjects since slower walking speeds typi-
cally indicate functional and mobility impairments.
Furthermore, this prediction equation is derived from
treadmill walking, which qualifies as a potential limi-
tation. During 6MW testing, subjects had to make tight
turns around a cone every 100 feet, which could have
had an adverse impact on distance covered and elicited a
higher energy expenditure in subjects with limited ability
to turn and/or balance impairments. Due to our small
sample size, we were unable to analyze potential co-
founders, such as height and how this may have affected
stride length, and subsequently economy of gait. Stride
length is known to influence walking economy in healthy
individuals [17]. Lastly, our subjects were limited in
range of PD severity (mild to moderate) due to entry
criteria, calling into question the generalizability of our
findings. Additionally, the lack of a relationship between
disease severity and economy of over-ground gait re-
ported in our study may have been attributed to this
small range of disease severity.

6. CONCLUSION

We conclude that PD causes major impairments in
over-ground gait economy, with clinical consequences
that include lower functional capacity. Based on the es-
ablished feasibility of such over-ground measures dem-
onstrated in this study, future clinicians and researchers
may wish to utilize these assessments in a number of
ways. Direct measures of over-ground gait economy
could serve as an index for determining response to
therapy, exercise interventions, and/or progression of
disease. Further, simultaneous measurements of gait
biomechanics during floor walking could yield clues
about the gait therapies that have the greatest potential
for reversing the decrements in gait economy that ac-
company PD.
7. ACKNOWLEDGEMENTS

This study was supported by VA RR&D Career Development Award-1 (Stookey), VA Merit Award funding (Ivey, Katzel, Anderson), Baltimore VA Medical Center Geriatric Research, Education and Clinical Center (GRECC), National Institute on Aging (NIA), Claude D. Pepper Older Americans Independence Center (P30-AG028747) and the Department of Veterans Affairs VA RR&D Exercise & Robotics Center of Excellence.

REFERENCES


